Azurity Pharmaceuticals Sues Lupin in Federal Drug Patent Case

Azurity Pharmaceuticals, Inc. sued Lupin Limited and related defendants in a case docketed as 25-cv-13133. The court issued a reassignment order on April 20, 2026, which is the only substantive docket entry visible at this stage.

No judge has been assigned yet, and the filing date remains unconfirmed in the available record.

The reassignment order suggests the case was transferred from one judge or docket track to another early in its life. That kind of administrative move is routine but can signal a related-case designation, a recusal, or a workload reassignment — the record does not yet say which.

Azurity is a specialty pharmaceutical company that has previously litigated patent disputes over branded drug formulations, particularly in the pediatric drug space. Lupin Limited is a major generic manufacturer with a long history of Hatch-Waxman patent challenges.

The pairing points toward a patent infringement suit tied to a generic drug application, though the complaint's specific claims are not yet detailed in the available docket.

No key issues have been formally identified in the record, no scheduling order has issued, and no judge is on the case. The litigation is effectively in its opening days. Until a judge is assigned and the complaint is fully processed, there is little to assess on the merits.